Form 4: Coeptis Therapeutics Holdings CEO Receives Stock Grant
Insider Transaction (Form 4)
David Elias Halabu, Chief Executive Officer and a Director of Coeptis Therapeutics Holdings, Inc., reported multiple transactions in common stock on April 27, 2026.
Summary
- Option exercise/conversion: acquired 19,737 Common Stock on July 27, 2026; holds 19,737 after (Direct).
- Grant/award: acquired 78,947 Restricted Stock Units on April 27, 2026; holds 78,947 after (Direct).
- Option exercise/conversion: disposed of 19,737 Restricted Stock Units on July 27, 2026; holds 59,210 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
David Elias Halabu — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-27 | Option exercise/conversion | Common Stock | 19,737 | — | — | 19,737 |
| 2026-04-27 | Grant/award | Restricted Stock Units | 78,947 | — | — | 78,947 |
| 2026-07-27 | Option exercise/conversion | Restricted Stock Units | 19,737 | — | — | 59,210 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-27 | Option exercise/conversion (19,737 shares) |
| 2026-04-27 | Grant/award (78,947 shares) |
| 2026-07-27 | Option exercise/conversion (19,737 shares) |
Keywords
insider transaction, Form 4, ZSQR, Z Squared Inc., neutral, David Elias Halabu
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.